US WorldMeds LLC
Latest From US WorldMeds LLC
Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings
Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.
Pink Sheet analysis of three years of novel US FDA approvals show the swiftest average time to approval in oncology, hematology, and antiviral divisions; neurology and hematology divisions contributed the most approvals.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- US WorldMeds LLC
- Senior Management
P. Breckinridge Jones, CEO
George Digenis, PhD, CSO
H. Lee Warren, Jr., COO
Stephanie Montgomery, VP, Fin.
Brian Jackey, VP, Global Operations & Quality
- Contact Info
US WorldMeds LLC
Phone: (866) 750-8796
4441 Springdale Rd.
Louisville, KY 40241
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.